Soluble tgf-b type III receptor fusion proteins
OwnerHerbert Lin, Elisabetta Del Re +2inventors
InventorsHerbert Lin, Elisabetta Del Re, William Crowley, Jodie Babitt
Life of this patent
Estimating the term…
Abstract
Soluble fusion proteins of the TGF-β type III receptor and novel methods for their production are disclosed herein for the first time. The fusion proteins of the invention competitively inhibit the binding of members of the TGF-β superfamily to their cell-surface receptors. Also provided are methods for using these fusion proteins to modulate the biological activity of members of the TGF-β superfamily under in vitro or in vivo conditions, and to prevent or treat a variety of pathophysiological conditions associated with overproduction of TGF-β or mediated by altered signaling pathways of the inhibin/activin system.
Claims69
A soluble fusion protein characterized in that it competitively inhibits the binding of members of the TGF-β superfamily to their cell-surface receptors, said fusion protein comprising at least one TGF-β type III receptor moiety covalently linked to at least one fusion moiety.
A soluble fusion protein characterized in that it competitively inhibits the binding of members of the TGF-β superfamily to their cell-surface receptors, said fusion protein comprising all or a portion of the Fc tail of human IgG covalently linked to all or an active portion of a splice variant of the extracellular domain of human TGF-β type III receptor, which extracellular domain is characterized in that it lacks two glycosaminoglycan chains.
Dependencies are inferred from the claim text.